Physician profile
Ashley Graves
NPI 1902324338
$5,145.78
in general payments reported to CMS, 2019-2025
23 companies · $19.48 in 2025
The $19.48 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,856 · 2022: $2,844 · 2023: $426 · 2025: $19.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $651.02 | 2021-2023 | Trintellix |
| Abbvie INC. | $592.20 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $558.47 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $522.34 | 2021-2023 | Abilify Maintena |
| Vanda Pharmaceuticals INC. | $504.90 | 2021-2022 | |
| Alkermes, INC. | $341.96 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $217.22 | 2022-2023 | Austedo |
| Sunovion Pharmaceuticals INC. | $216.76 | 2021-2022 | |
| Neos Therapeutics, LP | $200.73 | 2021-2023 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $199.99 | 2022-2023 | Ingrezza |
| Lundbeck LLC | $167.54 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $145.96 | 2021-2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $124.64 | 2021-2022 | |
| Bausch Health US, LLC | $121.43 | 2021-2022 | |
| Almatica Pharma LLC | $116.46 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $113.96 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $106.03 | 2022-2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $99.63 | 2022-2023 | Spravato |
| Eisai INC. | $84.76 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $20.05 | 2022 | |
| Adlon Therapeutics L.P. | $13.79 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.61 | 2021 | |
| Merck Sharp & Dohme LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.